Johan Van Limbergen
Overview
Explore the profile of Johan Van Limbergen including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
66
Citations
2558
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
11.
Colman R, Xiong Y, Mizuno T, Hyams J, Noe J, Boyle B, et al.
Aliment Pharmacol Ther
. 2021 Dec;
55(5):593-603.
PMID: 34935161
Background: Antibodies to infliximab (ATI) are associated with secondary loss of response and increased risk for drug reactions. Limited studies have associated ATI with increased infliximab clearance. Aims: We assessed...
12.
Sarbagili-Shabat C, Albenberg L, Van Limbergen J, Pressman N, Otley A, Yaakov M, et al.
Nutrients
. 2021 Nov;
13(11).
PMID: 34835992
Background: As the microbiome plays an important role in instigating inflammation in ulcerative colitis (UC), strategies targeting the microbiome may offer an alternative therapeutic approach. The goal of the pilot...
13.
Dierikx T, Berkhout D, Eck A, Tims S, Van Limbergen J, Visser D, et al.
Gut
. 2021 Nov;
71(9):1803-1811.
PMID: 34803023
Objective: Revised guidelines for caesarean section (CS) advise maternal antibiotic administration prior to skin incision instead of after umbilical cord clamping, unintentionally exposing the infant to antibiotics antenatally. We aimed...
14.
Malik A, Stringer E, Warner N, Van Limbergen J, Vandersteen A, Muise A, et al.
Pediatrics
. 2021 Oct;
148(5).
PMID: 34686572
Our understanding of inflammatory bowel disease is changing as we identify genetic variants associated with immune dysregulation. Inflammatory bowel disease undetermined, even when diagnosed in older children and adolescents, in...
15.
Dunn K, Forbrigger Z, Connors J, Rahman M, Cohen A, Van Limbergen J, et al.
Leuk Lymphoma
. 2021 Jul;
62(13):3244-3255.
PMID: 34279176
Treatment of pediatric acute lymphoblastic leukemia (ALL) with pegaspargase exploits ALL cells dependency on asparagine. Pegaspargase depletes asparagine, consequentially affecting aspartate, glutamine and glutamate. The gut as a confounding source...
16.
Meredith J, Henderson P, Wilson D, Van Limbergen J, Wine E, Russell R
J Pediatr Gastroenterol Nutr
. 2021 Mar;
73(1):54-60.
PMID: 33661242
Objectives: To assess current practices around the use of combination immunosuppression in paediatric inflammatory bowel disease (PIBD) with a focus on the subsequent withdrawal process. Methods: A web-based, 43-question survey....
17.
Uhlig H, Charbit-Henrion F, Kotlarz D, Shouval D, Schwerd T, Strisciuglio C, et al.
J Pediatr Gastroenterol Nutr
. 2020 Dec;
72(3):456-473.
PMID: 33346580
Background: It is important to identify patients with monogenic IBD as management may differ from classical IBD. In this position statement we formulate recommendations for the use of genomics in...
18.
Dunn K, Connors J, Bielawski J, Nearing J, Langille M, Van Limbergen J, et al.
Leuk Lymphoma
. 2020 Dec;
62(4):927-936.
PMID: 33258724
Asparaginase (ASNase) is an effective treatment of pediatric acute lymphoblastic leukemia (ALL). Changes in ASNase activity may lead to suboptimal treatment and poorer outcomes. The gut microbiome produces metabolites that...
19.
Liu L, Gu H, Van Limbergen J, Kenney T
Stat Med
. 2020 Nov;
40(4):897-919.
PMID: 33219557
In this article, we present a new variable selection method for regression and classification purposes, particularly for microbiome analysis. Our method, called subsampling ranking forward selection (SuRF), is based on...
20.
van Rheenen P, Aloi M, Assa A, Bronsky J, Escher J, Fagerberg U, et al.
J Crohns Colitis
. 2020 Oct;
PMID: 33026087
Objective: We aimed to provide an evidence-supported update of the ECCO-ESPGHAN guideline on the medical management of paediatric Crohn's disease [CD]. Methods: We formed 10 working groups and formulated 17...